Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate-timing Infanrix hexa pertussis vaccination immunogenicity and safety study
ACTRN12615000898550Phase 4Completed
- Sponsor
- Sydney Children's Hospitals Network
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertussis filamentous haemagglutinin in pertussis (2 arms), sponsored by Sydney Children's Hospitals Network. Primary endpoint: Primary immunogenicity endpoint. Started Jun 2013; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
pertussis
Beyond the preview
Go deeper on ACTRN12615000898550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000898550.